drugset / Trial / NCT01883011

A Study to Evaluate the Efficacy and Safety of Piracetam on Aphasia After Acute Ischemic Cerebral Artery Stroke

NCT01883011

Phase 4 Terminated 571 enrolled UCB Pharma
RandomizedParallel-groupDouble-blindTreatment

Summary

The aim of this study was to confirm the efficacy of piracetam after 12 weeks of treatment on the aphasic status of subjects suffering from aphasia after acute ischemic middle cerebral artery stroke and having received their medication within 7 h post-stroke onset.

Timeline

Start
1998-08
Primary completion
2001-07
Completion
2001-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Piracetam Small molecule 4.8 g Intravenous